228 related articles for article (PubMed ID: 16870779)
1. Killing kinetics of caspofungin, micafungin, and amphotericin B against Candida guilliermondii.
Cantón E; Pemán J; Sastre M; Romero M; Espinel-Ingroff A
Antimicrob Agents Chemother; 2006 Aug; 50(8):2829-32. PubMed ID: 16870779
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacodynamic characteristics of amphotericin B, caspofungin, fluconazole, and voriconazole against bloodstream isolates of infrequent Candida species from patients with hematologic malignancies.
Di Bonaventura G; Spedicato I; Picciani C; D'Antonio D; Piccolomini R
Antimicrob Agents Chemother; 2004 Nov; 48(11):4453-6. PubMed ID: 15504881
[TBL] [Abstract][Full Text] [Related]
3. The efficiency of the benzothiazole APB, the echinocandin micafungin, and amphotericin B in fluconazole-resistant Candida albicans and Candida dubliniensis.
Melkusová S; Bujdáková H; Volleková A; Myoken Y; Mikami Y
Pharmazie; 2004 Jul; 59(7):573-4. PubMed ID: 15296100
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata.
Barchiesi F; Spreghini E; Tomassetti S; Arzeni D; Giannini D; Scalise G
Antimicrob Agents Chemother; 2005 Dec; 49(12):4989-92. PubMed ID: 16304162
[TBL] [Abstract][Full Text] [Related]
5. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
Peter J; Armstrong D; Lyman CA; Walsh TJ
J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911
[TBL] [Abstract][Full Text] [Related]
6. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
Espinel-Ingroff A
Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
[TBL] [Abstract][Full Text] [Related]
7. In vitro interaction of micafungin and fluconazole against Candida.
Rodríguez MM; Ruiz M; Pastor FJ; Quindós G; Carrillo A; Guarro J
J Antimicrob Chemother; 2007 Jul; 60(1):188-90. PubMed ID: 17525050
[No Abstract] [Full Text] [Related]
8. Poor in vivo efficacy of caspofungin, micafungin and amphotericin B against wild-type Candida krusei clinical isolates does not correlate with in vitro susceptibility results.
Kardos T; Kovács R; Kardos G; Varga I; Bozó A; Tóth Z; Nagy F; Majoros L
J Chemother; 2018 Jul; 30(4):233-239. PubMed ID: 30025501
[TBL] [Abstract][Full Text] [Related]
9. Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against Aspergillus and Candida.
Warn PA; Sharp A; Guinea J; Denning DW
J Antimicrob Chemother; 2004 May; 53(5):743-9. PubMed ID: 15044422
[TBL] [Abstract][Full Text] [Related]
10. Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp.
Messer SA; Diekema DJ; Boyken L; Tendolkar S; Hollis RJ; Pfaller MA
J Clin Microbiol; 2006 Feb; 44(2):324-6. PubMed ID: 16455878
[TBL] [Abstract][Full Text] [Related]
11. In vitro interactions of micafungin with amphotericin B against clinical isolates of Candida spp.
Serena C; Mariné M; Quindós G; Carrillo AJ; Cano JF; Pastor FJ; Guarro J
Antimicrob Agents Chemother; 2008 Apr; 52(4):1529-32. PubMed ID: 18227181
[TBL] [Abstract][Full Text] [Related]
12. Micafungin activity against Candida bloodstream isolates: effect of growth medium and susceptibility testing method.
Pai MP; Jones AL; Mullen CK
Diagn Microbiol Infect Dis; 2007 May; 58(1):129-32. PubMed ID: 17240112
[TBL] [Abstract][Full Text] [Related]
13. Caspofungin in combination with amphotericin B against Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Giannini D; Scalise G
Antimicrob Agents Chemother; 2007 Mar; 51(3):941-5. PubMed ID: 17158939
[TBL] [Abstract][Full Text] [Related]
14. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide.
Mikamo H; Sato Y; Tamaya T
J Antimicrob Chemother; 2000 Sep; 46(3):485-7. PubMed ID: 10980180
[TBL] [Abstract][Full Text] [Related]
15. Caspofungin at catheter lock concentrations eradicates mature biofilms of Candida lusitaniae and Candida guilliermondii.
Simitsopoulou M; Kyrpitzi D; Velegraki A; Walsh TJ; Roilides E
Antimicrob Agents Chemother; 2014 Aug; 58(8):4953-6. PubMed ID: 24890585
[TBL] [Abstract][Full Text] [Related]
16. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin.
Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT
Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150
[TBL] [Abstract][Full Text] [Related]
18. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
[TBL] [Abstract][Full Text] [Related]
19. Effect of the growth medium on the in vitro antifungal activity of micafungin (FK-463) against clinical isolates of Candida dubliniensis.
Müller FM; Kurzai O; Hacker J; Frosch M; Mühlschlegel F
J Antimicrob Chemother; 2001 Nov; 48(5):713-5. PubMed ID: 11679561
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of caspofungin and micafungin, determined using the method of the European Committee on Antimicrobial Susceptibility Testing, against yeast isolates obtained in France in 2005-2006.
Dannaoui E; Lortholary O; Raoux D; Bougnoux ME; Galeazzi G; Lawrence C; Moissenet D; Poilane I; Hoinard D; Dromer F;
Antimicrob Agents Chemother; 2008 Feb; 52(2):778-81. PubMed ID: 18070978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
